Clinical Research Directory
Browse clinical research sites, groups, and studies.
Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors
Sponsor: Beijing Tiantan Hospital
Summary
Neurosurgery is a risk factor for delirium. Dexmedetomidine might reduce delirium by reducing neuroinflammation, improving postoperative analgesia and sleep quality. The the primary hypothesis is that perioperative administration of dexmedetomidine can reduce the incidence of postoperative delirium
Official title: Effect of Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors: a Randomized Placebo-controlled Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
366
Start Date
2024-01-25
Completion Date
2026-09-30
Last Updated
2025-02-17
Healthy Volunteers
No
Conditions
Interventions
Dexmedetomidine
In Dex group, dexmedetomidine will continue to be used during and after surgery, with a infusion of 0.4ug/kg/ h from anesthesia induction to dural closure, and then 0.08ug/kg/ h to 48 hours postoperatively.In placebo group, equivalent normal saline will be injected during operation, and the intravenous analgesia pump will not contain dexmedetomidine after operation
Locations (1)
Beijing Tiantan Hospital
Beijing, China